Annual Study Performance
Number of Studies (2021 - 2025)
5,809
Number of Studies by Substance
Studies Contributing to IND and NDA Submissions
-
in Korea, China, and
Southeast AsiaOver 60 Cases
-
US FDA
20 Cases
-
EMA
1 Case
-
Australia
4 Cases
-
First Korean
Biological Drug
-
First Korean
Botanical Drug
-
CNS drug, analgesic
related drug,
COPD drug, Botox etc